<code id='FBCC5AB7A5'></code><style id='FBCC5AB7A5'></style>

<acronym id='FBCC5AB7A5'></acronym>

<center id='FBCC5AB7A5'><center id='FBCC5AB7A5'><tfoot id='FBCC5AB7A5'></tfoot></center><abbr id='FBCC5AB7A5'><dir id='FBCC5AB7A5'><tfoot id='FBCC5AB7A5'></tfoot><noframes id='FBCC5AB7A5'>

<optgroup id='FBCC5AB7A5'><strike id='FBCC5AB7A5'><sup id='FBCC5AB7A5'></sup></strike><code id='FBCC5AB7A5'></code></optgroup>

<b id='FBCC5AB7A5'><label id='FBCC5AB7A5'><select id='FBCC5AB7A5'><dt id='FBCC5AB7A5'><span id='FBCC5AB7A5'></span></dt></select></label></b><u id='FBCC5AB7A5'></u>

~~<i id='FBCC5AB7A5'><strike id='FBCC5AB7A5'><tt id='FBCC5AB7A5'><pre id='FBCC5AB7A5'></pre></tt></strike></i>~~

Home» explore» focus

focus

focus

author：focus 2025-09-28 10:07:08 Page View：3

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

advertisement

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hyaluronic acid injections don’t help knee osteoarthritis, study finds
Next article： Moonlake's readout produced a cash windfall. Risks remain

explore

BioMarin wins approval for gene therapy to treat hemophilia A

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

AlexHogan/STATTocontainthespreadofCovid-19,Alaskaisplanningtotripleitsnumberofcontacttracers.Utahhas

Jerome Adams on the need for new antivirals for Covid

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Infant mortality in U.S. rose last year for first time in decades: CDC

APPhoto/EricGayTheU.S.infantmortalityraterose3%lastyear—thelargestincreaseintwodecades,accordingtoth

read more